Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06035744 · ClinicalTrials.gov registry record · Phase 1
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Cullinan Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
- 5
- Study locations
NCT06035744: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Cullinan Therapeutics.
NCT06035744 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Cullinan Therapeutics. The registered enrollment target is 86 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06035744, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Cullinan Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
- 5
- Study locations
Study Summary
CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors
Primary Outcome
Number of treatment-emergent events (TEAEs): TEAE is defined as adverse events reported for the first time or worsening of a pre-existing event after the first dose of study drug.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG CLN-617
Study Locations (5)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
Florida
- Orlando Health - Orlando
Illinois
- University of Chicago - Chicago
Texas
- MD Anderson - Houston
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2023-12-12 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What NCT06035744 shows while recruiting
NCT06035744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06035744 lists 5 locations in 5 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT06035744 about?
NCT06035744 is a clinical study titled "CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors". CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors
What is the current status of trial NCT06035744?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2023-12-12. Estimated completion is 2028-06.
What conditions does trial NCT06035744 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06035744?
The interventions under investigation include: Pembrolizumab (DRUG), CLN-617 (DRUG).
Who is sponsoring clinical trial NCT06035744?
This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06035744 being conducted?
This trial has 5 study locations across California, Florida, Illinois, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06035744's enrollment target sits among peer trials
86 130th of 189 higher than 58 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI